Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

ABSTRACT: To assess the dynamic changes in the immune contexture during early lung carcinogenesis, we performed immune profiling using the nCounter PanCancer Immune Profiling Panel on resected lung ADCs and their precursors .

ORGANISM(S): Homo sapiens

PROVIDER: GSE169033 | GEO | 2021/03/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression data for pathological stage I-II lung adenocarcinomas

Project description:Identification of genes up-regulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. To elucidate molecular characteristics of lung adenocarcinomas (ADCs) with ALK mutations and those without EGFR, KRAS and ALK mutations, 226 primary lung ADCs of pathological stage I-II, examined for the status of EGFR, KRAS and ALK mutations, were subjected to genome-wide expression profiling, and genes up-regulated in lung ADCs with ALK mutations and those without EGFR, KRAS and ALK mutations were identified. One hundred and seventy-four genes, including ALK, were selected as being up-regulated specifically in 79 lung ADCs without EGFR and KRAS mutations. These 79 cases were divided into: 11 cases of ALK-positive ADCs, 36 cases of group A triple-negative ADCs, and 32 cases of group B triple-negative ADCs, by unsupervised clustering according to the expression of the 174 genes. In ALK-positive ADCs, 30 genes, including ALK itself and GRIN2A, were significantly overexpressed. Group A triple-negative ADC cases showed significantly worse prognoses for relapse and death than ADC cases with EGFR, KRAS or ALK mutations and group B triple-negative ADC cases. Nine genes were identified as being significantly up-regulated in group A triple-negative ADC cases and critical for predicting their prognosis. The nine genes included DEPDC1, which had been identified as a candidate diagnostic and therapeutic target in bladder and breast cancers. Genes discriminating this group of ADCs will be useful for selection of patients who will benefit from adjuvant chemotherapy after surgical resection of stage I-II triple-negative ADCs and also informative for the development of molecular targeting therapies for these patients. Expression profiles in of 226 lung adenocarcinomas (127 with EGFR mutation, 20 with KRAS mutation, 11 with EML4-ALK fusion and 68 triple negative cases).

2011-11-01 | E-GEOD-31210 | biostudies-arrayexpress

Gene expression data for pathological stage I-II lung adenocarcinomas

2011-11-01 | GSE31210 | GEO

Programmed death 1 receptor blockade and immune-related gene expression profiling in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma

Project description:RNA from tumor samples from 65 patients with melanoma, lung cancer, head and neck treated anti-PD1was analyzed on the nCounter system using the PanCancer 730-Immune Panel.

2017-05-15 | GSE93157 | GEO

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

Project description:Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features

| PRJNA714945 | ENA

Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.

Project description:The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence (mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensively regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, lower infiltration of cytotoxic T cells (CTLs) and anti-tumor helper T cells (Th), higher infiltration of regulatory T cells (Tregs), decreased T cell clonality, and lower frequencies of top T cell clones in later-stages. Driver mutations, chromosomal copy number aberrations (CNAs) and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive ADC.

| S-EPMC8113327 | biostudies-literature

Spatially Resolved Transcriptomics Deconvolutes Histological Prognostic Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases

Project description:This bulk mRNA data was generated using the Nanostring ncounter platform using an io360 pancancer panel of 900 genes as part of a wider project which included spatial transcriptomic data generated using the Nanostring GeoMx platform. In this study we compared tissue surgical resected from patients with colorectal cancer and liver metastases.

2023-02-02 | GSE224235 | GEO

Gene expression profile of Leishmania major infected THP1 cell lines

Project description:Nanostring nCounter gene expression analysis on L. major infected wild type versus knockout THP1 cells was performed based on 784 genes with nCounter PanCancer Immune Profiling CS Kit (no MK).

2022-10-24 | GSE211590 | GEO

Project description:Gene expression of HGSC according to chemotherapeutic response was analyzed using Nanostring nCounter PanCancer Immune Profiling Panel.

2020-04-10 | GSE148392 | GEO

Transcriptomes of lung adenocarcinomas

Project description:We performed RNA-seq using 19 human surgically-resected lung adenocarcinomas to investigate of difference between EGFR-mutated and wild-type lung adenocarcinomas.

2020-02-25 | GSE141569 | GEO

Radiogenomics features of tumor dissemination in ABVD treated cHL patients

Project description:RNA extracted from diagnostic tumor samples of 126 patients affected by cHL was analyzed on the nCounter system using the PanCancer Immune Profiling Panel.

2023-01-11 | GSE184662 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data